<p><a href="http://us.rd.yahoo.com/dailynews/rss/business/*http://news.yahoo.com/s/nm/20051209/bs_nm/merck_dc"><img src="http://us.news3.yimg.com/us.i2.yimg.com/p/nm/20051209/2005_12_09t152908_450x266_us_merck.jpg?x=130&amp;y =76&amp;sig=Yf64mQC6GVdQWyOoIWzcaA--" align="left" height="76" width="130" alt="File photo shows bottles of the prescription arthritis and pain medication VIOXX September 30, 2004. As the first federal jury deliberates whether Merck and Co.'s painkiller Vioxx contributed to a Florida man's death, investors on Friday digested new claims that the battered company withheld key data about the drug's dangers. (Mike Segar/Reuters)" border="0" /></a>Reuters - As the first federal jury deliberates
whether Merck &amp; Co.'s painkiller Vioxx contributed to a
Florida man's death, investors on Friday digested new claims
that the battered company withheld key data about the drug's
dangers.</p><br clear=all>

View the entire article: Market weighs latest Vioxx blow (Reuters)